[HTML][HTML] CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - International Journal of …, 2021 - mdpi.com
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - IJERPH, 2021 - agris.fao.org
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
[PDF][PDF] CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - Int. J. Environ. Res …, 2021 - core.ac.uk
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - IJERPH, 2021 - econpapers.repec.org
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla… - … and public health, 2021 - pubmed.ncbi.nlm.nih.gov
Background The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla… - … and Public Health, 2021 - search.proquest.com
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab.
G Abbadessa, G Miele, P Cavalla… - … Research and Public …, 2021 - europepmc.org
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - IJERPH, 2021 - ideas.repec.org
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab
G Abbadessa, G Miele, P Cavalla… - INTERNATIONAL …, 2021 - iris.unicampania.it
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
[PDF][PDF] CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
G Abbadessa, G Miele, P Cavalla… - Int. J. Environ. Res …, 2021 - pdfs.semanticscholar.org
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …